Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Abogen Biosciences
AddedJul 2, 2026
UpdatedJul 2, 2026
Abogen Biosciences

Abogen Biosciences

Series C+

Abogen Biosciences is a clinical-stage biotechnology company developing mRNA drugs and vaccines for infectious diseases, oncology and autoimmune conditions.

HQ
Suzhou, Jiangsu, CN
Founded
2019
Overview
Compare
Fundraising
Employees
News
Website

Abogen Biosciences, founded in 2019 and headquartered in Suzhou, Jiangsu, China, has built a fully integrated mRNA platform covering protein engineering, sequence design, proprietary LNP delivery with Phase 3-validated ionizable lipids, formulation and GMP manufacturing. Its pipeline includes the ARCoV COVID-19 vaccine (first mRNA candidate to enter clinical trials in China), lyophilized RSV and shingles (VZV) vaccines, and oncology candidates such as ABO2203 CD3xCD19 bispecific T-cell engager and ABO2102 KRAS vaccine.

The company has raised over $1B including large Series C and C+ rounds with participation from Qiming Venture Partners and others, and maintains partnerships such as with Walvax for ARCoV. It focuses on thermostable formulations and in vivo expression technologies for vaccines and therapeutics.

Abogen Biosciences - Similar Companies

Rnaimmune logo

Rnaimmune

rnaimmune.com

Sensible Biotechnologies logo

Sensible Biotechnologies

sensible.bio

Abacus Bioscience logo

Abacus Bioscience

Abreos Biosciences logo

Abreos Biosciences

abreos.com

Abcombi Biosciences logo

Abcombi Biosciences

Moderna logo

Moderna

modernatx.com

Combined Therapeutics logo

Combined Therapeutics

combinedtx.com

Cisterna Biologics logo

Cisterna Biologics

cisternabx.com

Vernal Biosciences logo

Vernal Biosciences

vernal.bio

HDT Bio logo

HDT Bio

hdt.bio

Mana.bio logo

Mana.bio

mana.bio

Avenge Bio logo

Avenge Bio

avengebio.com

Abvc Biopharma logo

Abvc Biopharma

Excepgen logo

Excepgen

excepgen.com

Adze Biotechnology logo

Adze Biotechnology

adzebiotech.com

Abogen Biosciences - Quick Facts

Who are Abogen Biosciences' competitors?

Companies similar to Abogen Biosciences include Rnaimmune, Sensible Biotechnologies, Abacus Bioscience and Abreos Biosciences.

When was Abogen Biosciences founded?

Abogen Biosciences was founded in 2019.

Where is Abogen Biosciences' headquarters located?

Abogen Biosciences' headquarters is located in Suzhou, Jiangsu, CN.

When was Abogen Biosciences' last funding round?

Abogen Biosciences' most recent funding round was for $300M (USD) in November 2021.

How much has Abogen Biosciences raised to-date?

As of Nov 29, 2021, Abogen Biosciences has raised a total of $1B (USD).

Abogen Biosciences - Classification

Industry
  • Biotechnology
Model
  • Biotechnology
Tags
  • mRNA Therapeutics
  • Venture Capital Backed